Human immunodeficiency virus-associated progressive multifocal leucoencephalopathy: epidemiology and predictive factors for prolonged survival
Authors: Drake, A. K.1; Loy, C. T.2; Brew, B. J.; Chen, T. C. C.3; Petoumenos, K.4; Li, P. C. K.5; Wright, E. J.
Source: European Journal of Neurology, Volume 14, Number 4, April 2007 , pp. 418-423(6)
Publisher: Blackwell Publishing
- Free Content
- New Content
- Subscribed Content
- Free Trial Content
Abstract:
We performed a retrospective review of cases of human immunodeficiency virus-associated progressive multifocal leucoencephalopathy in four hospitals (three in Australia and one in Hong Kong) between 1987 and 2003 in order to describe the local experience with this disease and to evaluate parameters impacting upon survival. Eighty-seven cases were identified and demographic details, baseline parameters and treatment methods and response were described. Survival was substantially increased in the post-highly active antiretroviral therapy (HAART) era with a median survival increase from 14 to 64 weeks. On multivariate analysis, variables associated with prolonged survival included a CD4 count of >100 cells/μl at diagnosis and the use of HAART post-diagnosis, with no significant additional advantage from the use of neuroactive antiretrovirals.Keywords: antiretroviral therapy; human immunodeficiency virus; progressive multifocal leucoencephalopathy; survival
Document Type: Research article
DOI: 10.1111/j.1468-1331.2007.01686.x
Affiliations: 1: Infectious Diseases Unit, The Alfred Hospital, Melbourne, Vic., Australia 2: Departments of Neurology and HIV Medicine, St Vincent's Hospital, Sydney, NSW, Australia 3: University of New South Wales, Sydney, NSW, Australia 4: National Centre in HIV Epidemiology and Clinical Research, University of New South Wales, Sydney, NSW, Australia 5: Department of Medicine, Queen Elizabeth Hospital, Hong Kong, China; and
- Free Content
- New Content
- Subscribed Content
- Free Trial Content
Click here for Page Help